The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
GCLLSG 2016 | Key considerations for mutation detection in CLL
Anna Schuh, MD, PhD, MRCP, FRCPath of University of Oxford, Oxford, UK, discusses mutation detection using standardized next-generation sequencing (NGS) technology. Dr Schuh mentions that NGS method should be sensitive enough to detect mutations at a level of 1-5% and include testing for strong predictors of lack of response to chemoimmunotherapy and immunoglobulin gene rearrangement. In the UK, all patients participating in a trial of ibrutinib with rituximab for chronic lymphocytic leukaemia (FLAIR) participate in the whole genome sequencing (WGS), which is a source of unbiased data on the effect of treatment on patient populations. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.
